Asia-Pacific Oligonucleotides Market Growth Outlook: Expanding Role in Gene Therapy and Molecular Research
“The APAC Oligonucleotides Market is experiencing substantial growth, largely fueled by the increasing adoption of advanced genetic and molecular therapies in countries such as China, India, Japan, and South Korea. A heightened focus on precision medicine, gene therapy, and RNA-based therapeutics is significantly driving the demand for oligonucleotides in both research and clinical settings. Advancements in biotechnology, supportive government initiatives, and rising investments in life sciences are contributing to the market's expansion. Furthermore, the growing incidence of chronic and rare diseases is fostering the demand for targeted nucleic acid-based treatments. However, the market faces challenges due to high development costs and regulatory complexities, even as ongoing innovation continues to bolster long-term growth prospects. "
The Asia Pacific Tris Buffer market was valued at USD 963 Million in 2025 and is projected to reach USD 2,220 Million by 2033, with a compound annual growth rate (CAGR) of 19.40% from 2027 to 2033.
The presence of a robust contract research and manufacturing base, particularly in India and China, is enhancing the region's supply capabilities. Additionally, the rising prevalence of genetic disorders and infectious diseases is leading to greater adoption of oligonucleotide-based diagnostics and therapeutics. Collaborations between biotechnology firms and academic institutions are fostering innovation, while favorable regulatory policies are facilitating market expansion.
Furthermore, the affordability of skilled labor and advancements in nucleic acid synthesis technology are attracting international companies to establish production facilities in the region. Collectively, these factors position Asia Pacific as a high-growth market within the global oligonucleotides industry.
Increased funding in genomics, synthetic biology, and drug discovery is fueling demand.
The Asia Pacific region has seen substantial investments in pharmaceutical and biotechnology research, especially in China, India, and Japan. Both governments and private companies are funding projects in genomics, synthetic biology, and drug discovery, which is increasing the demand for oligonucleotides used in genetic testing, therapeutics, and molecular diagnostics. National initiatives such as China's Precision Medicine Initiative and India's Biotechnology Industry Research Assistance Council (BIRAC) are promoting innovation in this field.
Oligonucleotide-based treatments are being supported by developments in precision medicine.
The growing adoption of personalized medicine is increasing the demand for oligonucleotide-based therapies. Precision medicine relies on genetic profiling, and oligonucleotides play a vital role in the development of gene therapies, antisense drugs, and RNA-based treatments. Additionally, the rapidly expanding healthcare infrastructure in the Asia Pacific region and the rising awareness of targeted treatments are contributing to market growth.
Countries like China, India, and Japan are emerging as biotech hubs.
The Asia Pacific region is becoming a prominent global hub for biotechnology, with major pharmaceutical companies investing in research and development, as well as production facilities. The combination of established firms and innovative startups specializing in molecular diagnostics and gene therapies has created a strong ecosystem for oligonucleotide applications. Furthermore, growing collaborations between biotech companies and academic institutions are enhancing research and development efforts in the field.
India and China offer cost-effective and high-quality oligonucleotide synthesis.
Countries such as India and China have emerged as preferred destinations for oligonucleotide manufacturing, thanks to their cost-effective production capabilities and skilled workforce. Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in these countries offer high-quality oligonucleotide synthesis services, attracting pharmaceutical and biotech companies from around the world.
The need for molecular diagnostics and targeted therapies is surging.
The Asia Pacific region has a high prevalence of genetic disorders, such as thalassemia and sickle cell anemia, alongside emerging infectious diseases like COVID-19 and influenza. In response to these health challenges, there is a growing adoption of oligonucleotide-based diagnostics and therapeutics, including PCR-based testing and gene therapies.
Competitive Landscape
Some of the major companies operating within the Oligonucleotides market are: Thermo Fisher Scientific, Agilent Technologies, Inc., LGC Biosearch Technologies, Eurofins Scientific, Merck KGaA, Genepharma, Integrated DNA Technologies, Inc.,Avidity Biosciences and Others.